Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Related Keywords

,Real World Use ,Cell Therapy ,Diffuse Largeb Cell Lymphoma ,Dlbcl ,Relapsed Refractory Dlbcl ,Rr Dlbcl ,Second Line Therapy ,Second Line Treatment ,Later Line Therapy ,Later Line Treatment ,Cart Cell Therapy ,Cart Therapy ,Disease Burden ,Burden Of Disease ,Zuma1 ,Zuma 1 ,Real World Data ,Patient Factors ,Patient Status ,Crs ,Cytokine Release Syndrome ,Pelicans ,Immune Effector Cell Associated Neurotoxicity Syndrome ,Asco 2023 ,Asco Annual Meeting ,